ASTMH Annual Meeting 2026

blog
ASTMH Annual Meeting Blog - 2026 / All Blog Posts / 2026 / TropMed on the Potomac: Previewing the 2026 ASTMH Annual Meeting

TropMed on the Potomac: Previewing the 2026 ASTMH Annual Meeting

By: Matthew Davis, Burness

Photo: Astmh & 2026 11.17.26

TropMed on the Potomac: Previewing the 2026 ASTMH Annual Meeting

We’re on the eve of the premier global health gathering of the year. #TropMed26 officially starts Wednesday night just south of Washington, DC, on the banks of the Potomac River at Maryland’s National Harbor. The meeting gets underway with an opening keynote from Delese Mimi Amoakoa Darko, PhD, the director general of the African Medicines Agency (AMA), followed by four days of symposia, scientific sessions and poster presentations.

Science writer and TropMed Blogger Matthew Davis has been exploring the incredible offerings organized by Program Chair David Hamer, MD, and Associate Program Chair Kristy Murray, MD, DVM. Here are just a few highlights he’s selected—a mere skim of the offerings from a conference that provides more content than there are pundits, politicians and opinions in Washington, DC.

Thursday:

Avian Influenza in U.S. Dairy Workers: The time is ripe to hear from Rebecca Fischer, an epidemiologist and infectious disease expert at Texas A&M University School of Public Health. Earlier this month a dairy worker in Washington state died after being infected with H5N1 influenza and over the last 30 days six states have reported H5N1 infections in cattle herds.  Labor advocates worry that human cases are undercounted because farm workers may be reluctant to report symptoms.

Deadly Costs of Defunding Development: It’s painful but essential to take a deeper dive into evidence from recent studies that found severe cuts to development assistance could cause some 22.6 million deaths. This session will feature experts who are doing the hard work of revealing the terrible human costs of terminating support for global health initiatives.

Also Thursday:

  • Measles Comes Roaring Back in the Americas: Measles experts from across the Americas gather in the shadow of news reports that the U.S. has officially lost its measles elimination status. But it’s not just a U.S. problem. Since 2024, the region of the Americas has experienced a 32-fold increase in measles cases.
  •  Lingering Impact of Chikungunya in Children: A new study finds children infected with chikungunya appear more likely to suffer back and joint pain lasting up to 10 years. This is evidence of a “hidden” pediatric burden that should bolster the case for developing vaccines suitable for children.
  •  The Omnivore’s Dilemma, Lone Star Tick Edition: The tick species best known for transmitting a meat allergy, aka alpha-gal syndrome, is widely thought to feed primarily on deer. But a new study shows that the steady expansion of lone star ticks in the Eastern U.S. has been fueled by a blood buffet that also includes squirrel, chipmunk, rabbit, turkey and cats.

Friday:

A Year of Outbreaks: If one session has a claim being the scariest of #TropMed26, this one might be it. Experts will provide the latest insights regarding five headline-grabbing outbreaks of 2026: measles, Ebola-Bundibugyo virus, Andes virus (the species of Hantavirus involved in the cruise ship outbreak), cyclospora (the parasite linked to the summer outbreak of food-borne illness in the U.S.), and New World screwworm—a flesh-eating maggot that is a major threat to livestock.

Also of interest:

  • Stroll through the poster session to learn about, among other things, the large and largely hidden burden of dengue among U.S. citizens and the changes affecting the once obscure Oropouche virus that may be responsible its recent spread in Central and South America.   

Saturday:

Is Wolbachia Dengue’s Killer App? Over the last few years there has been encouraging evidence that releasing mosquitoes infected with a bacteria called Wolbachia can interrupt transmission of the world’s fastest growing mosquito-borne disease. Saturday, researchers will present results from multi-year EVITA trial that could make or break the case for using Wolbachia to combat dengue. It involved 6,000 school children in Brazil living in regions randomly divided between those receiving Wolbachia-infected mosquitoes and those where only standard control measures were employed—and evidence is gathered from blood tests that can reveal asymptomatic infections. It also just happened to be underway during the largest dengue outbreak ever recorded in Brazil.

Potential Revival of Discontinued Malaria Drug: Researchers at the University of Ghana found that genetic markers of resistance to chloroquine, a malaria drug discontinued decades ago because it was no longer effective, have nearly vanished from local parasite populations.

Sunday:

Building a New World Order for Global Health: Exiting #TropMed26 early will leave you disappointed. The closing keynote panel will feature Javid Abdelmoneim, MD, international president, Médecins Sans Frontières (MSF); Anthony S. Fauci, MD, now a distinguished university professor, Georgetown University School of Medicine; Nekoye Otsyula, MB, ChB, MS, global medical affairs director for malaria, Novartis; and John Nkengasong, MD, PhD, the former head of the Africa CDC who served as Global AIDS Coordinator in the Biden administration and is now executive director at the Mastercard Foundation.

Share this story